Equity · Healthcare
KURA
NASDAQKura Oncology, Inc.
The line runs $11 on 13 July through $11 on 23 September, on a scale from $8 to $14. Days the market did not trade hold the previous close, flat.
as of Sep 23, 2026
KURA insider trades
KURA has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 9 December 2025.
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 13 compensation filings in this window. The figures above count all of them.
KURA reported financials
SEC EDGARKURA reported revenue of $67.5M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$278.7M.
KURA earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
KURA institutional holders
SEC EDGAR8 of the 45 institutional funds we track reported a KURA position for the quarter ended 30 Jun 2026 — a combined $77.9M; the latest of those filings landed 02 Sep 2026.
KURA fails-to-deliver
SECOn 04 Sep 2026, 465 shares of KURA failed to deliver (about $6K).
Congressional trades in KURA
House disclosuresThe most recent congressional trade disclosed in KURA is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARValuation computed from SEC EDGAR filings